List of Excipients in Branded Drug TIGAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Henry Schein Inc	TIGAN	trimethobenzamide hydrochloride	0404-9964	CITRIC ACID MONOHYDRATE
Henry Schein Inc	TIGAN	trimethobenzamide hydrochloride	0404-9964	SODIUM CITRATE
Par Pharmaceutical Inc	TIGAN	trimethobenzamide hydrochloride	42023-118	CITRIC ACID MONOHYDRATE

TIGAN Excipient Strategy and Commercial Opportunities for Trimethobenzamide

Last updated: August 17, 2026

Tigan is the brand name for trimethobenzamide hydrochloride, an established antiemetic available primarily as a 300 mg oral capsule. Its core drug substance has limited remaining exclusivity value because the product has been marketed for decades. Commercial opportunity is therefore concentrated in formulation execution: improved oral disintegration, liquid or orally disintegrating dosage forms, injectable presentations, patient-friendly packaging, and supply reliability.

The strongest near-term strategy is a differentiated generic or 505(b)(2) product that uses established excipients, avoids unnecessary formulation complexity, and addresses settings where vomiting limits oral drug administration.

What is Tigan and which dosage forms are commercially relevant?

Tigan contains trimethobenzamide hydrochloride, an antiemetic used for nausea and vomiting. The marketed oral product is a 300 mg capsule. Public FDA labeling identifies the product as a prescription medicine and provides dosing, contraindications, warnings, and inactive-ingredient information.[1]

Product attribute	Commercial assessment
Active ingredient	Trimethobenzamide hydrochloride
Brand	Tigan
Primary marketed form	300 mg oral capsule
Therapeutic class	Antiemetic
Likely regulatory route for a standard generic	ANDA under section 505(j)
Regulatory route for a differentiated dosage form	505(b)(2) NDA
Current patent value	Low for the legacy active ingredient
Main commercial barriers	Manufacturing consistency, supply reliability, FDA approval, formulation differentiation
Most relevant excipient opportunities	Capsule fill optimization, taste masking, fast disintegration, oral liquid, ODT, injectable stability

Tigan is not a biologic, so biosimilar competition is not relevant. Competition will come from generic trimethobenzamide products and other antiemetics, including ondansetron, metoclopramide, promethazine, prochlorperazine, and oral or injectable alternatives.

What excipients are used in Tigan capsules?

The Tigan capsule formulation uses conventional pharmaceutical excipients. Public product labeling should be treated as the controlling source for the marketed product because supplier formulations can change over time.[1]

Common excipient functions in trimethobenzamide capsules include:

Excipient function	Commercial purpose
Diluent	Provides capsule-fill volume and controls dose uniformity
Glidant	Improves powder flow during encapsulation
Lubricant	Reduces tooling and capsule-machine friction
Disintegrant	Promotes release of trimethobenzamide hydrochloride
Capsule shell	Provides dosage-form integrity and patient identification
Colorant or opacifier	Supports product appearance and brand differentiation

A generic developer should not assume that copying the qualitative excipient profile is sufficient. The relevant formulation targets are blend uniformity, dissolution, content uniformity, capsule brittleness, moisture sensitivity, and stability across the intended shelf life.

How should an excipient strategy for trimethobenzamide be designed?

The most defensible strategy is to use a conservative, compendial excipient platform for an ANDA and reserve novel excipient combinations for a 505(b)(2) product with a clear clinical or commercial benefit.

1. Optimize capsule performance before pursuing a new dosage form

For a conventional 300 mg capsule, the highest-value formulation work is likely to involve:

• Consistent powder flow at commercial scale
• Low segregation risk during blending
• Rapid and reproducible disintegration
• Dissolution performance across relevant pH conditions
• Reduced capsule-fill weight where feasible
• Low moisture uptake
• Compatibility with high-speed encapsulation
• Stable appearance and mechanical strength

Trimethobenzamide hydrochloride is a salt form, which may support conventional immediate-release formulation. The development risk is less likely to be discovery of a novel drug-delivery mechanism than achieving robust manufacturing performance at a competitive cost.

2. Select excipients with established regulatory precedent

Excipients should have compendial status or a strong FDA Inactive Ingredient Database precedent for the intended route and dosage form.[2] The preferred platform would typically use:

• A common capsule diluent such as lactose, microcrystalline cellulose, or another established filler
• A conventional disintegrant
• Colloidal silicon dioxide or another established glidant where needed
• Magnesium stearate or another conventional lubricant at a controlled concentration
• A gelatin or hypromellose capsule shell

The selection should account for patient populations that may have lactose intolerance, dietary restrictions, gelatin restrictions, or sensitivity to colorants. A capsule that removes avoidable excipients can support institutional formulary positioning, but the benefit must be large enough to justify separate manufacturing and regulatory work.

3. Use excipient reduction as a commercial differentiator

An excipient-reduced trimethobenzamide capsule could target:

• Hospital formularies
• Long-term-care facilities
• Patients with dietary or religious restrictions
• Buyers seeking simplified inactive-ingredient profiles
• Pharmacy benefit managers seeking multiple-source supply

The value proposition should be based on measurable attributes, such as reduced allergen concern, lower pill burden, improved stability, or improved tolerability. A simple "clean label" claim without a clinically relevant distinction is unlikely to support a durable price premium.

What formulation patents could protect a new Tigan product?

A conventional trimethobenzamide capsule is unlikely to support strong new patent protection merely through routine excipient substitution. A patent position becomes more credible when the formulation produces a defined technical result.

Potential claim categories include:

Patent area	Potential claim subject	Strength assessment
Immediate-release capsule	Specific excipient ratios and dissolution profile	Low to moderate
Orally disintegrating tablet	Rapid disintegration with acceptable taste	Moderate if data are strong
Oral liquid	Chemical stability, preservative system, or suspension control	Moderate
Injectable formulation	Preservative-free stability, container compatibility, or ready-to-use presentation	Moderate
Taste masking	Coating or ion-exchange approach with defined release	Moderate
Manufacturing process	Granulation, blending, or drying process that improves uniformity	Moderate
Packaging	Moisture-control packaging linked to product stability	Low to moderate

Patent strength depends on unexpected results, narrow but commercially meaningful claim scope, and freedom from obviousness challenges. A patent covering only a routine combination of lactose, a disintegrant, and magnesium stearate would face material validity risk.

The legacy Tigan product is old, and publicly available FDA materials do not indicate a commercially meaningful current Orange Book patent barrier for standard trimethobenzamide capsules.[3] Any developer should verify the current Orange Book entry and patent listings before relying on that conclusion for a filing or launch decision.

When does Tigan lose exclusivity and what is the generic-entry risk?

Tigan's original market exclusivity and any early composition-of-matter protection expired long ago. The product therefore has a mature generic profile rather than a branded exclusivity timeline.

Exclusivity issue	Assessment
Original drug approval	Historical approval; marketed for decades
New chemical entity exclusivity	Expired
Original composition patents	Expected to be expired
Current Orange Book patent risk	No material barrier apparent for the legacy capsule based on public FDA resources
Paragraph IV exposure	Possible only if a relevant unexpired listed patent exists
Standard generic entry	Primarily dependent on ANDA approval and commercial economics
180-day first-filer value	Potentially limited by market size and number of potential applicants

For an ANDA applicant, the principal regulatory question is whether the reference-listed drug has any active listed patents or exclusivity. If none apply, a Paragraph IV certification may not be necessary. If an active patent is listed, an applicant could use a Paragraph IV certification, triggering the statutory notice and potential 30-month stay framework under the Hatch-Waxman Act.[4]

A standard generic is more likely to face price competition than patent litigation. The commercial risk is that multiple manufacturers can enter with similar capsules, compressing margins before a late entrant recovers development and validation costs.

What FDA pathways are available for new trimethobenzamide formulations?

ANDA pathway for an equivalent capsule

An ANDA is the most direct route for a product that matches the reference-listed drug in active ingredient, dosage form, strength, route, and performance. The applicant must demonstrate pharmaceutical equivalence and bioequivalence, provide chemistry, manufacturing, and controls data, and meet applicable labeling requirements.[5]

This route is appropriate for:

• A 300 mg immediate-release capsule
• A conventional excipient substitution
• A product with no new clinical indication
• A formulation designed to match the reference product's release profile

505(b)(2) pathway for differentiated delivery

A 505(b)(2) application may be more suitable for:

• An orally disintegrating tablet
• An oral solution or suspension
• A new injectable presentation
• A ready-to-administer product
• A formulation supported by bridging studies rather than a full independent clinical program

The sponsor would need to establish the relevance of the listed drug's safety and efficacy data while generating product-specific data for the new formulation.[6]

Pediatric opportunity

A pediatric dosage form could have commercial value if it addresses swallowing difficulty or enables weight-based dosing. A liquid, powder for reconstitution, or rapidly disintegrating unit dose could be more useful than a conventional capsule in pediatric care. The regulatory and clinical burden would increase, particularly for dosing accuracy, palatability, microbial control, and age-appropriate administration.

What oral and injectable formulations offer the best commercial opportunity?

Orally disintegrating tablet

An ODT could address patients who are nauseated, have difficulty swallowing, or need administration without water. The main formulation issues are:

• Taste masking
• Mechanical strength
• Rapid disintegration
• Moisture protection
• Low friability
• Dose uniformity
• Packaging that preserves stability

A conventional sweetener or flavor system may be inadequate because trimethobenzamide hydrochloride can produce an unacceptable oral sensation. Taste masking may require polymer coating, complexation, ion exchange, or a multiparticulate approach. Each technique raises manufacturing and regulatory complexity.

Oral liquid

An oral solution or suspension could enable pediatric and geriatric dosing. Its commercial weaknesses are higher packaging cost, microbial-control requirements, shipping weight, dose-measurement risk, and potential chemical instability.

A suspension could be more practical than a true solution if solubility or taste limits are significant. The formulation would need controlled sedimentation, easy redispersion, accurate dosing, and an appropriate preservative system. FDA excipient precedent and the product's pH range would be central to development.[2]

Injectable product

An injectable trimethobenzamide product could address patients who cannot retain oral medication. The opportunity is operational rather than patent-driven. Important requirements include:

• Sterility assurance
• Particulate control
• Container-closure compatibility
• pH and osmolality control
• Shelf-life stability
• Preservative selection or a preservative-free presentation
• Prefilled syringe or ready-to-use packaging

A ready-to-administer syringe could reduce preparation time and medication-error risk in emergency departments and institutional settings. Its value would depend on whether the injectable reference product is currently marketed and whether hospitals maintain meaningful demand for trimethobenzamide over competing injectable antiemetics.

Which companies are challenging Tigan and how competitive is the market?

The relevant competitive set is broader than products containing trimethobenzamide. Generic manufacturers can compete through the same active ingredient, while branded and generic antiemetics compete for the same clinical use.

Competitor category	Examples	Competitive effect
Same-ingredient generics	Trimethobenzamide hydrochloride capsules	Direct price competition
Serotonin antagonist	Ondansetron	Strong prescribing and formulary competition
Dopamine antagonist	Metoclopramide, prochlorperazine	Alternative mechanisms and dosage forms
Antihistamine/anticholinergic	Promethazine and related products	Compete in selected nausea indications
Hospital injectable products	Multiple antiemetic injectables	Compete for acute-care use

Public information does not establish a current high-value patent litigation campaign around standard trimethobenzamide capsules. The expected dispute profile is therefore lower than for recently approved drugs with active composition, formulation, or method-of-use patents.

What licensing deals and manufacturing barriers affect Tigan opportunities?

No major publicly documented licensing transaction is central to the commercial position of legacy Tigan. A transaction would more likely concern manufacturing capacity, an established abbreviated application, a finished-dose supply agreement, or rights to a differentiated dosage form.

The main manufacturing barriers are:

• Qualified trimethobenzamide hydrochloride API supply
• Consistent particle-size distribution
• Powder flow and blend uniformity
• Control of moisture and degradation
• Capsule-shell supply
• Validation of dissolution across scale
• Backup manufacturing capacity
• Stability data sufficient for the target shelf life

API sourcing can become a more important barrier than intellectual property. A low-price generic program with a single qualified API supplier has meaningful continuity risk. Dual sourcing may reduce supply risk but can require additional comparability work and regulatory documentation.

How strong is the patent estate for Tigan?

The patent estate for the legacy Tigan capsule appears weak from a lifecycle-management perspective.

Estate component	Strategic value
Original active-ingredient patents	Expired or commercially irrelevant
Standard capsule formulation	Limited new-patent potential
Method-of-use patents	Possible only for a genuinely differentiated indication or regimen
ODT or liquid formulation	Moderate opportunity with supporting data
Injectable presentation	Moderate opportunity if technical advantages are demonstrated
Manufacturing process patents	Useful as defensive rights, but often difficult to enforce
Trade secrets	Important for process control and supply reliability

The strongest protection would likely combine a narrow formulation patent with regulatory differentiation, manufacturing know-how, and reliable distribution. A formulation patent alone would not prevent multiple conventional generic entrants.

What revenue exposure and launch scenarios exist for Tigan?

Product-level Tigan revenue is not reliably disclosed in current public filings. The commercial model should therefore use scenario analysis rather than assume branded-drug economics.

Launch scenario	Product	Commercial outlook
Low-investment generic	300 mg capsule	Fastest route, lowest differentiation, high price pressure
Supply-reliability generic	Capsule with dual-source API and dependable availability	Potential institutional value
Patient-friendly product	ODT or taste-masked dosage form	Higher development cost, possible premium
Pediatric product	Oral liquid or unit-dose powder	Targeted market, greater formulation burden
Acute-care product	Ready-to-use injectable	Potential hospital value, dependent on market demand
Portfolio strategy	Capsule plus ODT or liquid	Broader coverage but higher operational complexity

A conventional capsule may succeed only at low cost and with efficient manufacturing. An ODT or injectable product has more room for differentiation but requires stronger evidence of clinical, operational, or adherence benefit.

Key Takeaways

• Tigan contains trimethobenzamide hydrochloride and is primarily associated with a 300 mg oral capsule.
• Original drug exclusivity and legacy patent protection have expired.
• The principal opportunity is formulation and supply-chain execution, not recovery of old-molecule exclusivity.
• A conventional ANDA capsule offers the lowest regulatory risk but also the greatest price pressure.
• ODT, oral liquid, pediatric, and ready-to-use injectable products offer stronger differentiation under a 505(b)(2) strategy.
• Excipient selection should prioritize FDA precedent, dissolution performance, moisture control, taste masking, and manufacturing robustness.
• No material current biosimilar issue applies because trimethobenzamide is a small molecule.
• Public information does not indicate a major current patent-litigation or licensing campaign around standard Tigan capsules.
• The most defensible commercial position would combine a differentiated dosage form with dual-source API, stable manufacturing, and institutional distribution.

FAQs

Can trimethobenzamide be reformulated as an orally disintegrating tablet?

Yes. An ODT is technically feasible, but taste masking, moisture protection, mechanical strength, and rapid disintegration would drive development risk. A 505(b)(2) pathway may be appropriate if the product is materially different from the reference capsule.

Is a trimethobenzamide oral solution commercially attractive?

It may be attractive for pediatric, geriatric, and dysphagia populations. The business case depends on stability, preservative requirements, dosing accuracy, and whether the target market is large enough to support liquid-product manufacturing.

Does Tigan have biosimilar competition?

No. Trimethobenzamide hydrochloride is a small-molecule drug. Competition is through generic versions and alternative antiemetic products, not biosimilars.

Can a new excipient combination obtain a patent for Tigan?

Possibly, but routine excipient substitution is vulnerable to obviousness challenges. Stronger claims would require a defined technical effect, such as improved taste masking, faster disintegration, enhanced stability, or a clinically meaningful release profile.

What is the lowest-risk commercial entry strategy for trimethobenzamide?

A conventional 300 mg immediate-release capsule using established excipients and a standard ANDA pathway is the lowest-risk route. Its commercial success would depend on manufacturing cost, supply continuity, product availability, and the number of competing generic suppliers.

References

1. U.S. National Library of Medicine. (n.d.). DailyMed: Tigan and trimethobenzamide hydrochloride prescribing information. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Amendments and patent certification procedures. FDA.
5. U.S. Food and Drug Administration. (2013). ANDA submissions: Content, format, and review. FDA.
6. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). FDA.